



Evolving Paradigm of Curative Intent Breast Cancer Management

Guest Editors:

Dr. Patricia Tang

Tom Baker Cancer Centre,
Calgary, AB T2N 4N2, Canada

Dr. Jeffrey Cao

Tom Baker Cancer Centre,
Calgary, AB T2N 4N2, Canada

Deadline for manuscript
submissions:

closed (30 April 2022)

Message from the Guest Editors

Dear Colleagues,

The care of breast cancer has evolved significantly over the past decade, with personalized medicine and biomarkers influencing decision-making in the curative setting. Within each breast cancer receptor subtype (hormone receptor positive, HER-2 positive, and triple-negative), recent advances are influencing the sequencing of curative therapy. Studies are assessing both escalation and de-escalation of treatment intensity in specific sub-groups of patients. Additional research suggests adjunct lifestyle interventions (such as exercise) also can play a significant role in improving treatment tolerance and compliance, while also impacting cancer outcomes.

This special issue will focus on the current status and challenges in treating breast cancer in the curative setting. It will encompass therapeutic advances in systemic therapy for breast cancer across the receptor subtypes as well as radiotherapy. The role of adjunct lifestyle interventions (both during and after treatment), to help improve the care of breast cancer patients, will also be reviewed.

